US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Apnimed, Inc.

News headline image
Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Apnimed, Inc.
Via GlobeNewswire
Tickers APMD
News headline image
Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update
From Apnimed, Inc.
Via GlobeNewswire
Tickers APMD
News headline image
Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Apnimed, Inc.
Via GlobeNewswire
Tickers APMD
News headline image
Apnimed Announces a Robust Slate of Presentations at SLEEP 2024, Including an Analysis of the Prevalence of Obesity in Obstructive Sleep Apnea
From Apnimed, Inc.
Via GlobeNewswire
News headline image
Apnimed Announces Completion of Enrollment in Phase 3 LunAIRo Study of AD109, the Potential First Nighttime Oral Treatment for Obstructive Sleep Apnea
From Apnimed, Inc.
Via GlobeNewswire
News headline image
Apnimed Named 2024 Best Places to Work Company by the Boston Business Journal
From Apnimed, Inc.
Via GlobeNewswire
News headline image
Apnimed to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Apnimed, Inc.
Via GlobeNewswire
News headline image
Apnimed to Participate in the Upcoming Leerink Partners Global Biopharma Conference
From Apnimed, Inc.
Via GlobeNewswire
News headline image
Apnimed to Participate in the Upcoming Evercore ISI 2024 Emerging Biotech Conference
From Apnimed, Inc.
Via GlobeNewswire
News headline image
Apnimed Announces New Leadership Appointments as the Company Builds Its Commercial and Human Resource Capabilities in Support of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea
From Apnimed, Inc.
Via GlobeNewswire
News headline image
Apnimed Announces First Patient Dosed in SynAIRgy, the Second Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea
From Apnimed, Inc.
Via GlobeNewswire
News headline image
Apnimed to Participate in Upcoming November Investor Conferences
From Apnimed, Inc.
Via GlobeNewswire
News headline image
Apnimed Announces Launch of Joint Venture with Shionogi to Develop Novel Pharmacologic Therapies for Obstructive Sleep Apnea and other Sleep Disorders
From Apnimed, Inc.
Via GlobeNewswire
News headline image
Apnimed to Present Review of Recent Data on Investigational Pharmacologic Treatment for Obstructive Sleep Apnea at World Sleep 2023
From Apnimed, Inc.
Via GlobeNewswire
News headline image
Apnimed to Participate in Upcoming October Investor Conferences
From Apnimed, Inc.
Via GlobeNewswire
News headline image
American Journal of Respiratory and Critical Care Medicine Publishes Full, Positive Results of Apnimed’s MARIPOSA Study on AD109, an Investigational Oral Drug for Obstructive Sleep Apnea
From Apnimed, Inc.
Via GlobeNewswire
News headline image
Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors
From Apnimed, Inc.
Via GlobeNewswire
News headline image
Apnimed Announces First Patient Dosed in LunAIRo, the First Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea
From Apnimed, Inc.
Via GlobeNewswire
News headline image
Apnimed Appoints John Yee, MD, MPH, as SVP, Medical Affairs
From Apnimed, Inc.
Via GlobeNewswire
News headline image
Apnimed to Present New Data on Investigational Oral Therapies for Obstructive Sleep Apnea at ERS International Congress 2023
From Apnimed, Inc.
Via GlobeNewswire
News headline image
APNIMED to Participate in Upcoming Investor Conferences in September
From Apnimed, Inc.
Via GlobeNewswire
News headline image
Fierce Biotech Names Apnimed a 2023 “Fierce 15” Biotech Company
From Apnimed, Inc.
Via GlobeNewswire
News headline image
APNIMED to Participate in the 43rd Annual Canaccord Genuity Global Growth Conference
From Apnimed, Inc.
Via GlobeNewswire
News headline image
Apnimed to Participate in the William Blair Virtual Conference: Transitioning Biotech Breakthroughs to Commercial Success
From Apnimed, Inc.
Via GlobeNewswire
News headline image
Apnimed to Participate in the 2023 BIO International Convention
From Apnimed, Inc.
Via GlobeNewswire
News headline image
Apnimed Presented Positive Phase 2b Results on AD109, an Investigational Oral Drug for Obstructive Sleep Apnea, for the First Time at ATS 2023
From Apnimed, Inc.
Via GlobeNewswire
News headline image
Apnimed to Present Positive Phase 2b Results on AD109, an Investigational Oral Treatment for Obstructive Sleep Apnea, at ATS 2023
From Apnimed, Inc.
Via Business Wire
News headline image
Apnimed to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Apnimed, Inc.
Via Business Wire
News headline image
Apnimed to Participate in the SVB Securities Global Biopharma Conference
From Apnimed, Inc.
Via Business Wire
News headline image
Apnimed Completes Oversubscribed $79.75 Million Series C Extension Financing to Fund Two Planned Phase 3 Trials of AD109, an Oral Medication with the Potential to Be the First Therapy for Direct Treatment of Obstructive Sleep Apnea (OSA)
From Apnimed, Inc.
Via Business Wire